Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Colorectal Neoplasms 36Breast Neoplasms 29Pancreatic Neoplasms 20Rectal Neoplasms 17Stomach Neoplasms 16Neoplasm Metastasis 16Neoplasms 12Esophageal Neoplasms 8Triple Negative Breast Neoplasms 7Colonic Neoplasms 7Colorectal Cancer Metastatic 6Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Brain Neoplasms 4Adenocarcinoma 4Head and Neck Neoplasms 3Gastrointestinal Neoplasms 3Biliary Tract Neoplasms 3Bile Duct Neoplasms 3Advanced Solid Tumors 3Sarcoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Liver Neoplasms 2Diabetes Mellitus, Insulin-Dependent, 12 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2

Interventions

Cyclophosphamide 4blinatumomab 3Azacitidine 3venetoclax 2tetrathiomolybdate 1tagraxofusp 1siremadlin 1sabatolimab 1posaconazole 1pembrolizumab 1midostaurin 1fludarabine phosphate 1fludarabine 1daratumumab 1avelumab 1aflutinib 1Whole-Body Irradiation 1Sirolimus 1Mycophenolic Acid 1Monatide (IMS 3015) 1Midazolam 1Melphalan 1Injections 1Idarubicin 1Daunorubicin 1Cytarabine 1Celecoxib 1Capecitabine 1Biological Assay 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasm, Residual × Capecitabine × Clear all
NCT06134375 2026-04-20

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Dartmouth-Hitchcock Medical Center

Phase 1/2 Recruiting
204 enrolled
Breast

Neoplasm, Residual, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡